Resveratrol acts via melanoma-associated antigen A12 (MAGEA12)/protein kinase B (Akt) signaling to inhibit the proliferation of oral squamous cell carcinoma cells

References

• Thomson PJ. Perspectives on oral squamous cell carcinoma prevention-proliferation, position, progression and prediction. J Oral Pathol Med. 2018;47(9):803–807.
   PubMed Web of Science ®Google Scholar
• Jiang S, Dong Y. Human papillomavirus and oral squamous cell carcinoma: a review of HPV-positive oral squamous cell carcinoma and possible strategies for future. Curr Probl Cancer. 2017;41(5):323–327.
   PubMed Web of Science ®Google Scholar
• Omura K. Current status of oral cancer treatment strategies: surgical treatments for oral squamous cell carcinoma. Int J Clin Oncol. 2014;19(3):423–430.
   PubMed Web of Science ®Google Scholar
• Mollaoglu N, Vairaktaris E, Nkenke E, et al. Expression of MAGE-A12 in oral squamous cell carcinoma. Dis Markers. 2008;24(1):27–32.
   PubMed Web of Science ®Google Scholar
• Faiena I, Astrow SH, Elashoff DA, et al. Melanoma-associated antigen-A and programmed death-ligand 1 expression are associated with advanced urothelial carcinoma. Cancer Immunol Immunother. 2019;68(5):743–751.
   PubMed Web of Science ®Google Scholar
• Shirakura Y, Mizuno Y, Wang L, et al. T-cell receptor gene therapy targeting melanoma-associated antigen-A4 inhibits human tumor growth in non-obese diabetic/SCID/γcnull mice. Cancer Sci. 2012;103(1):17–25.
   PubMed Web of Science ®Google Scholar
• Wu J, Wang J, Shen W. Identification of MAGEA12 as a prognostic outlier gene in gastric cancers. Neoplasma. 2017;64(2):238–243.
   PubMed Web of Science ®Google Scholar
• Yanagi T, Nagai K, Shimizu H, et al. Melanoma antigen A12 regulates cell cycle via tumor suppressor p21 expression. Oncotarget. 2017;8(40):68448–68459.
   PubMedGoogle Scholar
• Song M, Bode AM, Dong Z, et al. AKT as a therapeutic target for cancer. Cancer Res. 2019;79(6):1019–1031.
   PubMed Web of Science ®Google Scholar
• Revathidevi S, Munirajan AK. Akt in cancer: mediator and more. Semin Cancer Biol. 2019;59:80–91.
   PubMed Web of Science ®Google Scholar
• Brown JS, Banerji U. Maximising the potential of AKT inhibitors as anti-cancer treatments. Pharmacol Ther. 2017;172:101–115.
   PubMed Web of Science ®Google Scholar
• Alzahrani AS. PI3K/Akt/mTOR inhibitors in cancer: at the bench and bedside. Semin Cancer Biol. 2019;59:125–132.
   PubMed Web of Science ®Google Scholar
• Mei XL, Zhong S. Long noncoding RNA LINC00520 prevents the progression of cutaneous squamous cell carcinoma through the inactivation of the PI3K/Akt signaling pathway by downregulating EGFR. Chin Med J (Engl). 2019;132(4):454–465.
   PubMed Web of Science ®Google Scholar
• Kim DJ, Lee MH, Liu K, et al. Herbacetin suppresses cutaneous squamous cell carcinoma and melanoma cell growth by targeting AKT and ODC. Carcinogenesis. 2017;38(11):1136–1146.
   PubMed Web of Science ®Google Scholar
• Yang Y, Chen D, Liu H, et al. Increased expression of lncRNA CASC9 promotes tumor progression by suppressing autophagy-mediated cell apoptosis via the AKT/mTOR pathway in oral squamous cell carcinoma. Cell Death Dis. 2019;10(2):41–53.
   PubMed Web of Science ®Google Scholar
• Moraes JK, Wagner VP, Fonseca FP, et al. Activation of BDNF/TrkB/Akt pathway is associated with aggressiveness and unfavorable survival in oral squamous cell carcinoma. Oral Dis. 2019;25(8):1925–1936.
   PubMed Web of Science ®Google Scholar
• Bao Q, Chen S, Qin H, et al. Constitutive β-catenin activation in osteoblasts impairs terminal osteoblast differentiation and bone quality. Exp Cell Res. 2017;350(1):123–131.
   PubMed Web of Science ®Google Scholar
• Shimura T. Targeting the AKT/cyclin D1 pathway to overcome intrinsic and acquired radioresistance of tumors for effective radiotherapy. Int J Radiat Biol. 2017;93(4):381–385.
   PubMed Web of Science ®Google Scholar
• Chai R, Fu H, Zheng Z, et al. Resveratrol inhibits proliferation and migration through SIRT1 mediated post-translational modification of PI3K/AKT signaling in hepatocellular carcinoma cells. Mol Med Rep. 2017;16(6):8037–8044.
   PubMed Web of Science ®Google Scholar
• Mirhadi E, Roufogalis BD, Banach M, et al. Resveratrol: mechanistic and therapeutic perspectives in pulmonary arterial hypertension. Pharmacol Res. 2021;163:105287.
   PubMed Web of Science ®Google Scholar
• Lin J, Lin L, Thomas DG, et al. Melanoma-associated antigens in esophageal adenocarcinoma: identification of novel MAGE-A10 splice variants. Clin Cancer Res. 2004;10(17):5708–5716.
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhou K, Ma L, et al. MicroRNA-145 overexpression inhibits neuroblastoma tumorigenesis in vitro and in vivo. Bioengineered. 2020;11(1):219–228.
   PubMed Web of Science ®Google Scholar
• Cai L, Ye L, Hu X, et al. MicroRNA miR-330-3p suppresses the progression of ovarian cancer by targeting RIPK4. Bioengineered. 2021;12(1):440–449.
   PubMed Web of Science ®Google Scholar
• Endo M, Kanda M, Sawaki K, et al. Tissue expression of melanoma-associated antigen A6 and clinical characteristics of gastric cancer. Anticancer Res. 2019;39(11):5903–5910.
   PubMed Web of Science ®Google Scholar
• Jia B, Zhao X, Wang Y, et al. Prognostic roles of MAGE family members in breast cancer based on KM-Plotter data. Oncol Lett. 2019;18(4):3501–3516. .
   PubMed Web of Science ®Google Scholar
• Sang M, Lian Y, Zhou X, et al. MAGE-A family: attractive targets for cancer immunotherapy. Vaccine. 2011;29(47):8496–8500.
   PubMed Web of Science ®Google Scholar
• De Smet C, Loriot A, Boon T. Promoter-dependent mechanism leading to selective hypomethylation within the 5ʹ region of gene MAGE-A1 in tumor cells. Mol Cell Biol. 2004;24(11):4781–4790.
   PubMed Web of Science ®Google Scholar
• De Smet C, Lurquin C, Lethe B, et al. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol. 1999;19(11):7327–7335.
   PubMed Web of Science ®Google Scholar
• Abd-Elsalam EA, Ismaeil NA. Melanoma-associated antigen genes: a new trend to predict the prognosis of breast cancer patients. Med Oncol. 2014;31(11):285–296.
   PubMed Web of Science ®Google Scholar
• Mollaoglu N, Vairaktaris E, Nkenke E, et al. Expression of MAGE-A12 in oral squamous cell carcinoma. Dis Markers. 2008;24(1):27–32.
   PubMed Web of Science ®Google Scholar
• Lian Y, Sang M, Gu L, et al. MAGE-A family is involved in gastric cancer progression and indicates poor prognosis of gastric cancer patients. Pathol Res Pract. 2017;213(8):943–948.
   PubMed Web of Science ®Google Scholar
• Liang Z, Xu J, Ma Z, et al. MiR-187 suppresses non-small-cell lung cancer cell proliferation by targeting FGF9. Bioengineered. 2020;11(1):70–80.
   PubMed Web of Science ®Google Scholar
• Zhao G, Bae JY, Zheng Z, et al. Overexpression and implications of melanoma-associated antigen A12 in pathogenesis of human cutaneous squamous cell carcinoma. Anticancer Res. 2019;39(4):1849–1857.
   PubMed Web of Science ®Google Scholar
• Yanagi T, Nagai K, Shimizu H, et al. Melanoma antigen A12 regulates cell cycle via tumor suppressor p21 expression. Oncotarget. 2017;8(40):68448–68459.
   PubMedGoogle Scholar
• Li DW, Dai CS, Yang XY, et al. Critical role of p21 on olaquindox-induced mitochondrial apoptosis and S-phase arrest involves activation of PI3K/AKT and inhibition of Nrf2/HO-1pathway. Food Chem Toxicol. 2017;108(Pt A):148–160.
   PubMed Web of Science ®Google Scholar
• Song M, Bode AM, Dong Z, et al. AKT as a Therapeutic Target for Cancer. Cancer Res. 2019;79(6):1019–1031.
   PubMed Web of Science ®Google Scholar
• Brown JS, Banerji U. Maximising the potential of AKT inhibitors as anti-cancer treatments. Pharmacol Ther. 2017;172:101–115.
   PubMed Web of Science ®Google Scholar
• Alzahrani AS. PI3K/Akt/mTOR inhibitors in cancer: at the bench and bedside. Semin Cancer Biol. 2019;59:125–132.
   PubMed Web of Science ®Google Scholar
• Yan Y, Yan F, Huang Q. MiR-200c inhibited the proliferation of oral squamous cell carcinoma cells by targeting Akt pathway and its downstream Glut1. Arch Oral Biol. 2018;96:52–57.
   PubMed Web of Science ®Google Scholar
• Gao L, Dou ZC, Ren WH, et al. CircCDR1as upregulates autophagy under hypoxia to promote tumor cell survival via AKT/ERK(½)/mTOR signaling pathways in oral squamous cell carcinomas. Cell Death Dis. 2019;10(10):745–754.
   PubMed Web of Science ®Google Scholar
• Yousef M, Vlachogiannis IA, Tsiani E. Effects of resveratrol against lung Cancer: in vitro and in vivo studies. Nutrients. 2017;9(11):E1231.
   PubMed Web of Science ®Google Scholar
• Kim YN, Choe SR, Cho KH, et al. Resveratrol suppresses breast cancer cell invasion by inactivating a RhoA/YAP signaling axis. Exp Mol Med. 2017;49(2):e296.
   PubMed Web of Science ®Google Scholar
• Uzawa K, Amelio AL, Kasamatsu A, et al. Resveratrol targets urokinase-type plasminogen activator receptor expression to overcome cetuximab-resistance in oral squamous cell carcinoma. Sci Rep. 2019;9(1):12179.
   PubMed Web of Science ®Google Scholar
• Chen L, Xia JS, Wu JH, et al. Resveratrol inhibits oral squamous cell carcinoma cells proliferation while promoting apoptosis through inhibition of CBX7 protein. Environ Toxicol. 2020;35(11):1234–1240.
   PubMed Web of Science ®Google Scholar
• Kim SE, Shin SH, Lee JY, et al. Resveratrol induces mitochondrial apoptosis and inhibits epithelial-mesenchymal transition in oral squamous cell carcinoma cells. Nutr Cancer. 2018;70(1):125–135.
   PubMed Web of Science ®Google Scholar
• Yu XD, Yang JL, Zhang WL, et al. Resveratrol inhibits oral squamous cell carcinoma through induction of apoptosis and G2/M phase cell cycle arrest. Tumour Biol. 2016;37(3):2871–2877.
   PubMed Web of Science ®Google Scholar